[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"relapsed-adult-acute-myeloid-leukemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:relapsed-adult-acute-myeloid-leukemia":43},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100552364",false,"NCT06472128","Novel Digital Application for Patients With Acute Leukemia","Multi-Site Randomized Controlled Trial of a Novel Digital Application (DREAMLAND) to Improve Outcomes for Patients With Acute Myeloid Leukemia","NAVIGATE","Inclusion Criteria:\n\n* Hospitalized patients (age \\> 18 years) with a diagnosis of AML.\n* Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +\u002F- additional agents or modification of this regimen on a clinical trial.\n* Ability to comprehend and speak English as the digital apps are only available in English\n\nNote: Patients newly diagnosed as well as those with relapsed\u002Frefractory AML initiating treatment with intensive or HMA-based chemotherapy will be eligible to participate.\n\nExclusion Criteria:\n\n* Patients with a diagnosis of acute promyelocytic leukemia\n* Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.","ALL","18 Years","120 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.",[27,28,29],"Relapsed Adult Acute Myeloid Leukemia","Primary Refractory Acute Myeloid Leukemia","High Risk Acute Myeloid Leukemia","RECRUITING","2025-11-06",{"date":33,"type":34},"2025-11-10","ACTUAL",{"date":36,"type":34},"2024-10-21",{"date":38,"type":21},"2030-04-30",{"name":40,"class":41},"Massachusetts General Hospital","OTHER",3,""]